initial public offerings (IPOs) trading on American exchanges

Tuesday, October 2, 2018

Tricida (TCDA) began trading on the Nasdaq on Thur 28 June 18

Tricida, Inc. focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. 
  • Sector(s): Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 57
  • Incorporated in 2013
  • Headquartered in South San Francisco, California

No comments:

Post a Comment